Brachytherapy technology now available nationwide

TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product’s developer, and BrachySciences.

“This agreement places new technology that can improve prostate cancer treatment outcomes directly in the hands of doctors to benefit their patients,” said Robert G. Mills, Envisioneering president.

According to Mills, TargetScan addresses unmet treatment planning and brachytherapy seed placement needs of radiation oncologists. In addition to eliminating prostate movement during treatments, the system offers improved 3-D imaging, with views of both sagittal and transverse planes.